Establishment Labs (NASDAQ:ESTA – Get Rating) had its price target dropped by Stephens from $90.00 to $87.00 in a research report issued to clients and investors on Wednesday, The Fly reports. Stephens’ target price would suggest a potential upside of 44.71% from the company’s previous close.
Several other analysts have also recently commented on ESTA. BTIG Research raised their price objective on shares of Establishment Labs from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Friday, October 7th. Mizuho started coverage on shares of Establishment Labs in a research note on Wednesday, October 12th. They issued a “buy” rating and a $70.00 price objective for the company. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $97.00.
Establishment Labs Stock Down 4.5 %
ESTA stock opened at $60.12 on Wednesday. The company has a debt-to-equity ratio of 97.56, a quick ratio of 3.29 and a current ratio of 4.27. Establishment Labs has a one year low of $44.03 and a one year high of $93.80. The company has a fifty day moving average of $61.28 and a 200-day moving average of $59.58. The stock has a market capitalization of $1.46 billion, a PE ratio of -19.33 and a beta of 1.09.
Establishment Labs (NASDAQ:ESTA – Get Rating) last announced its quarterly earnings data on Monday, November 7th. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.27). Establishment Labs had a negative net margin of 49.50% and a negative return on equity of 209.77%. The company had revenue of $38.25 million during the quarter, compared to analyst estimates of $37.55 million. During the same quarter last year, the business earned ($0.61) EPS. As a group, analysts expect that Establishment Labs will post -2.6 EPS for the current year.
Hedge Funds Weigh In On Establishment Labs
Several hedge funds have recently added to or reduced their stakes in ESTA. BNP Paribas Arbitrage SA grew its holdings in shares of Establishment Labs by 3,244.4% during the first quarter. BNP Paribas Arbitrage SA now owns 602 shares of the company’s stock worth $41,000 after buying an additional 584 shares in the last quarter. Lazard Asset Management LLC grew its holdings in shares of Establishment Labs by 104.5% during the first quarter. Lazard Asset Management LLC now owns 963 shares of the company’s stock worth $64,000 after buying an additional 492 shares in the last quarter. BNP Paribas Arbitrage SNC grew its holdings in shares of Establishment Labs by 100.6% during the third quarter. BNP Paribas Arbitrage SNC now owns 1,689 shares of the company’s stock worth $92,000 after buying an additional 847 shares in the last quarter. Bank of America Corp DE grew its holdings in shares of Establishment Labs by 38.4% during the first quarter. Bank of America Corp DE now owns 2,227 shares of the company’s stock worth $150,000 after buying an additional 618 shares in the last quarter. Finally, Twin Lakes Capital Management LLC purchased a new stake in shares of Establishment Labs during the third quarter worth about $163,000. 75.26% of the stock is currently owned by hedge funds and other institutional investors.
Establishment Labs Company Profile
Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander, as well as distributes Puregraft line of products for autologous adipose tissue harvesting and redistribution.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Establishment Labs, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Establishment Labs wasn’t on the list.
While Establishment Labs currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Source: news.google.com
